Accelerating trials site selection for a rare disease

An unnamed biopharmaceutical company planning a late-stage clinical trial for a rare disease needed to identify suitable trial sites and principal investigators with access to the right patient populations. It used Clarivate's Cortellis granular site data combined with incidence/prevalence and U.S. claims data, supplemented by custom investigator-ranking analysis from Clarivate Consulting Services. The page states this integrated approach saved time, improved clinical-operations efficiency, and gave the sponsor confidence in meeting enrollment targets for the trial. No specific numeric outcome is given.

The customer is anonymised in Clarivate’s own case study — not withheld by us.

Clarivate owns Cortellis, the curated competitive-intelligence and pipeline-tracking platform standard in pharma portfolio-management teams.

This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.